

```
VAR G1=C/S
REP G2=(0-3) CH2
ENTER (DIS), GRA, NOD, BON OR ?:end
L26  STRUCTURE CREATED

=> s l26
SAMPLE SEARCH INITIATED 15:24:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  14599 TO ITERATE

  6.8% PROCESSED    1000 ITERATIONS                              0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       284745 TO   299215
PROJECTED ANSWERS:               0 TO        0

L27           0 SEA SSS SAM L26

=> s l26 ful
FULL SEARCH INITIATED 15:24:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 292683 TO ITERATE

 60.7% PROCESSED  177691 ITERATIONS                             20 ANSWERS

 86.8% PROCESSED  254172 ITERATIONS                             20 ANSWERS

 98.9% PROCESSED  289523 ITERATIONS                             20 ANSWERS

 98.9% PROCESSED  289523 ITERATIONS                             20 ANSWERS

 98.9% PROCESSED  289523 ITERATIONS                             20 ANSWERS

 98.9% PROCESSED  289523 ITERATIONS                             20 ANSWERS

 99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)       22 ANSWERS

 99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)       22 ANSWERS

 99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)       22 ANSWERS

 99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)       22 ANSWERS

 99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)       22 ANSWERS
```

```
99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)      22 ANSWERS
99.7% PROCESSED  291829 ITERATIONS  (      2 INCOMPLETE)      22 ANSWERS
```

```
=> s l28
L29           6 L28

=> d his

     (FILE 'HOME' ENTERED AT 15:06:54 ON 24 NOV 2004)

     FILE 'CAPLUS' ENTERED AT 15:07:03 ON 24 NOV 2004
L1            0 S VLA!(L)PIPERIDIN?
L2            0 S LVA?(L)PIPERIDIN?
L3           22 S VLA?(L)PIPERIDIN?

     FILE 'REGISTRY' ENTERED AT 15:09:30 ON 24 NOV 2004
L4              STRUCT
L5            0 S L4
L6            1 S L4 FUL

     FILE 'CAPLUS' ENTERED AT 15:14:01 ON 24 NOV 2004
L7            1 S L6

     FILE 'REGISTRY' ENTERED AT 15:14:40 ON 24 NOV 2004
L8              STRUC
L9            0 S L8
L10           0 S L8 FUL
L11             STRUC
L12             STRUC
L13           0 S L12
L14           1 S L12 FUL
L15             STRUC
L16           0 S L15
L17             STRUC
L18           0 S L17
L19           1 S L17 FUL

     FILE 'REGISTRY' ENTERED AT 15:23:06 ON 24 NOV 2004
L20             STRUC
L21           0 S L20
L22           1 S L20 FUL
L23             STRUC
L24           0 S L23
L25           1 S L23 FUL
L26             STRUC
L27           0 S L26
L28          27 S L26 FUL

     FILE 'CAPLUS' ENTERED AT 15:40:16 ON 24 NOV 2004
L29           6 S L28

=> s l27 not l7
              0 L27
L30           0 L27 NOT L7

=> s l29 not l7
L31           5 L29 NOT L7

=> d bib abs hitstr 1-5

L31  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:346236  CAPLUS
DN   141:140744
TI   Synthesis and histone deacetylase inhibitory activity of cyclic
```

tetrapeptides containing a retrohydroxamate as zinc ligand
AU Nishino, Norikazu; Yoshikawa, Daisuke; Watanabe, Louis A.; Kato, Tamaki; Jose, Binoy; Komatsu, Yasuhiko; Sumida, Yuko; Yoshida, Minoru
CS Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, Kitakyushu, 808-0196, Japan
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2427-2431
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
GI



I

AB Cyclic tetrapeptide retrohydroxamic acids I (m = 1, 2; n = 1, 2, 3; R = H, Me) were prepared as histone deacetylase (HDAC) inhibitors. The results show that they have potential as anticancer drugs.

IT **727426-47-3P 727426-48-4P 727426-49-5P**
727426-50-8P 727426-51-9P 727426-54-2P
727426-55-3P 727426-56-4P 727426-57-5P
727426-58-6P 727426-61-1P 727426-62-2P
727426-63-3P 727426-64-4P 727426-65-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and histone deacetylase inhibitory activity of potential antitumor cyclic tetrapeptides containing retrohydroxamate as zinc ligand)

RN 727426-47-3 CAPLUS
CN L-Lysine, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-formyl-N6-(phenylmethoxy)-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-48-4 CAPLUS
CN L-Lysine, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-acetyl-N6-(phenylmethoxy)-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-49-5 CAPLUS
CN Heptanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-7-[formyl(phenylmethoxy)amino]-, 2-(trimethylsilyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-50-8 CAPLUS
CN Heptanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-7-[acetyl(phenylmethoxy)amino]-2-amino-, 2-(trimethylsilyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-51-9 CAPLUS
CN Octanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-8-[formyl(phenylmethoxy)amino]-, 2-(trimethylsilyl)ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-54-2 CAPLUS
CN L-Lysine, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-formyl-N6-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-55-3 CAPLUS
CN L-Lysine, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-acetyl-N6-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-56-4 CAPLUS

CN Heptanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-7-[formyl(phenylmethoxy)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-57-5 CAPLUS

CN Heptanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-7-[acetyl(phenylmethoxy)amino]-2-amino-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-58-6 CAPLUS

CN Octanoic acid, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-8-[formyl(phenylmethoxy)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-61-1 CAPLUS
CN L-Lysine, O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-formyl-N6-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-62-2 CAPLUS
CN L-Lysine, O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-N6-acetyl-N6-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 727426-63-3 CAPLUS
CN Heptanoic acid, O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-7-[formyl(phenylmethoxy)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
RN    727426-64-4   CAPLUS
CN    Heptanoic acid, O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-7-
      [acetyl(phenylmethoxy)amino]-2-amino-, (2S)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.
```



```
RN    727426-65-5   CAPLUS
CN    Octanoic acid, O-methyl-D-tyrosyl-L-isoleucyl-2-piperidinecarbonyl-2-amino-
      8-[formyl(phenylmethoxy)amino]-, (2S)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.
```



```
RE.CNT  29     THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31  ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:777794  CAPLUS
DN   139:276811
TI   Preparation of spiro heterocyclic derivatives and adhesion molecule
     inhibitors comprising the same
IN   Ishigaki, Takeshi; Taniguchi, Koji; Kainoh, Mie; Meguro, Hiroyuki;
     Ishizaka, Yoko
PA   Toray Industries, Inc., Japan
SO   PCT Int. Appl., 132 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2003080611        A1    20031002    WO 2003-JP3324         20030319
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
```

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI JP 2002-80697 A 20020322
OS MARPAT 139:276811
GI



I

AB The patent relates to the preparation of spiro derivs. similar to I, which have an excellent effect of inhibiting cell adhesion mediated by adhesion mols., in particular, adhesion mol. VLA-4 and, therefore, are useful as remedies for various inflammatory diseases. The adhesion mol. inhibitors are useful in preventing and treating inflammatory diseases caused by the infiltration of leukocytes such as monocytes, lymphocytes and eosinophils by inhibiting cell infiltration mediated by adhesion mols., in particular, adhesion mol. VLA-4. Thus, 2-[(1-acetyl-piperidin-2-yl)carbonylamino]-3-[(2,4,8-triaza-1-oxo-4-phenylspiro[4.5]dec-8-yl)carbonylamino]propanoic acid (I), prepared by hydrolysis of the corresponding Me ester which was made by reacting 1-acetyl-piperidin-2-carboxylic acid with 2-[(tert-butoxy)carbonylamino]-3-[(2,4,8-triaza-1-oxo-4-phenylspiro[4.5]dec-8-yl)carbonylamino]propanoic acid Me ester, was tested for inhibiting adhesion mol. VLA-4 and had IC50 of 65 nM.

IT **607366-18-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of spiro heterocyclic derivs. for use as adhesion mol. inhibitors)

RN 607366-18-7 CAPLUS

CN L-Alanine, N-[(1-acetyl-2-piperidinyl)carbonyl]-3-[[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **607366-19-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro heterocyclic derivs. for use as adhesion mol. inhibitors)
RN 607366-19-8 CAPLUS
CN L-Alanine, N-[(1-acetyl-2-piperidinyl)carbonyl]-3-[[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:661401 CAPLUS
DN 137:332742
TI Unique Overlap in the Prerequisites for Thrombin Inhibition and Oral Bioavailability Resulting in Potent Oral Antithrombotics
AU Adang, Anton E. P.; de Man, Adrianus P. A.; Vogel, Gerard M. T.; Grootenhuis, Peter D. J.; Smit, Martin J.; Peters, Co A. M.; Visser, Arie; Rewinkel, Jos B. M.; van Dinther, Theo; Lucas, Hans; Kelder, Jan; van Aelst, Sjoerd; Meuleman, Dick G.; van Boeckel, Constant A. A.
CS Research and Development, Lead Discovery Unit Chemistry Group, NV Organon, Neth.
SO Journal of Medicinal Chemistry (2002), 45(20), 4419-4432
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:332742
GI



I

AB Despite intense research over the last 10 yr, aided by the availability of X-ray structures of enzyme-inhibitor complexes, only very few truly orally

```
         active thrombin inhibitors have been found.  We conducted a comprehensive
         study starting with peptide transition state analogs (TSA).  Both
         hydrophobic nonpeptide analogs as well as hydrophilic peptidic analogs
         were synthesized.  The bioavailability in rats and dogs could be
         drastically altered depending on the overall charge distribution in the
         mol.  Compound I, a tripeptide TSA inhibitor of thrombin, showed an oral
         bioavailability of 32% in rats and 71% in dogs, elimination half-lives
         being 58 and 108 min, resp.  The thrombin inhibition constant of compound I
         was 1.1 nM, and in an in vivo arterial flow model, the ED50 was 5.4
         nmol/kg·min, comparable to known non-TSA inhibitors.  A mol. design
         was found that combines antithrombotic efficiency with oral
         bioavailability at low dosages.
IT       722493-09-6
         RL: RCT (Reactant); RACT (Reactant or reagent)
            (preparation, thrombin-inhibitory activity and bioavailability of diketo and
            heterocyclic peptidomimetics)
RN       722493-09-6  CAPLUS
CN       Heptanoic acid, 3-[[[(2S)-1-[(2R)-2-[(carboxymethyl)amino]-3-cyclohexyl-1-
         oxopropyl]-2-piperidinyl]carbonyl]amino]-7-[[(1,1-
         dimethylethoxy)carbonyl]amino]-2-oxo-, (3S)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



```
RE.CNT  50     THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31   ANSWER 4 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN    1999:640697  CAPLUS
DN    131:267045
TI    Peptidomimetic antagonists for treatment of CD11/CD18 adhesion
      receptor-mediated disorders
IN    Burdick, Daniel J.
PA    Genentech, Inc., USA
SO    PCT Int. Appl., 230 pp.
      CODEN: PIXXD2
DT    Patent
LA    English
FAN.CNT 1
      PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
      ---------------     ----   --------    --------------------   --------
PI    WO 9949856           A2    19991007    WO 1999-US6410         19990324
      WO 9949856           A3    19991118
          W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
              DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
              JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
            MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
            TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
            MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2325986          AA    19991007    CA 1999-2325986        19990324
    AU 9931137          A1    19991018    AU 1999-31137          19990324
    AU 764524           B2    20030821
    EP 1063982          A2    20010103    EP 1999-912869         19990324
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR 9909418          A     20010925    BR 1999-9418           19990324
    NZ 506779           A     20030829    NZ 1999-506779         19990324
    ZA 2000004653       A     20011211    ZA 2000-4653           20000905
    NO 2000004800       A     20001124    NO 2000-4800           20000926
PRAI US 1998-79732P     P     19980327
    WO 1999-US6410      W     19990324
OS   MARPAT 131:267045
AB   Peptidomimetic compds. (Markush included) that are useful for treating
     Mac-1- or LFA-1-mediated disorders,e.g. inflammatory disorders, allergies,
     and autoimmune diseases, are provided.
IT   245464-90-8P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (peptidomimetic antagonists for treatment of CD11/CD18 adhesion
        receptor-mediated disorders)
RN   245464-90-8  CAPLUS
CN   L-Lysine, N2-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl
     ]-N6-[[1-(1-oxopropyl)-2-piperidinyl]carbonyl]- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



```
L31  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   1972:127400  CAPLUS
DN   76:127400
TI   Synthesis of lipophilic-substituted ACTH peptides
AU   Brugger, M.
CS   Div. Pharm., Ciba-Geigy A.-G., Basel, Switz.
SO   Helvetica Chimica Acta (1971), 54(4), 1261-74
     CODEN: HCACAV; ISSN: 0018-019X
DT   Journal
LA   German
AB   The ACTH peptide [D-Ser1,Lys17,18]-β-corticotropin-(1,19)-
     nonadecapeptide was substituted at the proline terminal by NH2, NH(CH2)nMe
     (n = 4, 9, 15, 23), NH[(CH2)7Me]2, NHCH[(CH2)16Me]2, OH, O(CH2)nMe (n = 9,
```

13, 17, 23), or OCH[(CH2)16Me]2. The peptides substituted by NH(CH2)15Me, O(CH2)13Me, and O(CH2)17Me showed oral corticotropic activity in hypophysectomized rats, comparable to that of the free acid. The 1st 2 of these also showed prolonged high activity when given subcutaneously.

IT **36163-13-0P 36243-21-7P 36243-33-1P**
36357-13-8P 36477-91-5P 36521-32-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36163-13-0 CAPLUS

CN L-Prolinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(1-heptadecyloctadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36243-21-7 CAPLUS

CN L-Prolinamide, N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(1-heptadecyloctadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36243-33-1 CAPLUS

CN L-Prolinamide, N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-prolyl-L-valylglycyl-N6-[(1,1-dimethylethoxy)-carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(1-heptadecyloctadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 36357-13-8 CAPLUS

CN L-Prolinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl-L-prolyl-L-valylglycyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-(1-heptadecyloctadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 36477-91-5 CAPLUS
CN α1-19-Corticotropin, 1-[N-[(1,1-dimethylethoxy)carbonyl]-L-serine]-11-[N6-[(1,1-dimethylethoxy)carbonyl]-L-lysine]-15-[N6-[(1,1-dimethylethoxy)carbonyl]-L-lysine]-16-[N6-[(1,1-dimethylethoxy)carbonyl]-L-lysine]-17-[N6-[(1,1-dimethylethoxy)carbonyl]-L-lysine]-18-[N6-[(1,1-dimethylethoxy)carbonyl]-L-lysine]-19-[N-(1-heptadecyloctadecyl)-L-prolinamide]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 36521-32-1 CAPLUS

CN α1-19-Corticotropin, 1-D-serine-17-L-lysine-18-L-lysine-19-[N-(1-heptadecyloctadecyl)-L-prolinamide]-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 47931-10-2

CMF C141 H235 N31 O24 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





CM 2

CRN 64-19-7
CMF C2 H4 O2